Our Psychedelic Trip Isn’t Over I don’t know the first thing about psychedelics. Rather, that’s what I would have been saying back in 2020 when the psychedelics sector…
Filament
Counting to Four $25.537M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has been issued a fourth patent for the extraction and standardization of natural psilocybin and…
Natural Psychedelics Revolution $21.418M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has entered into an exclusive licensing agreement with Psyence Group Inc. (PSYG.C). Under the terms…
Patent Issuance $18.123M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has been issued a patent by the United States Patent and Trademark Office (USPTO) for the…
Meeting with the FDA $18.123M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has held a pre-investigational new drug application (PIND) meeting with the FDA Division…
A Transformative Year $18.123M Market Capitalization Filament Health Corp. (FH.NE) today released its Q4 2021 financial results and has provided operational highlights for the period ended December 31, 2021….
Natural Talent Albert Hofmann was a fun guy, pun intended. More importantly, the Swiss chemist is known for being the first person to synthesize, consume, and learn of the psychedelic…
Two for Two $23.066M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has been issued a second patent by the Canadian Intellectual Property Office (CIPO) for the…
Problematic Psychedelics? Psychedelics and mental health treatment go together like orange juice and toothpaste. That’s what I would have said five years ago. Prior to the publication of multiple…
Filament Health (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial using PEX010, the Company’s botanical psilocybin drug candidate. Cybin Therapeutics…